Navigation Links
The role of stem cells in developing new drugs
Date:10/31/2012

The potential therapeutic applications of stem cells such as regenerating damaged tissues or organs have generated a great deal of interest over the past decade. While these types of applications are exciting, it is a long journey from lab to clinic. The most immediate impact of stem cells on human health will most likely come from their use in the development of new drugs.

The ability to generate stem cells by reprogramming cells from patients' skin has revolutionised human stem cell research. These cells, known as human induced pluripotent stem cells (hIPSC), can be differentiated into almost any cell type, allowing the opportunity to have a ready source of human cells for testing new therapies. DefiniGEN, a new spin-out company from the University of Cambridge, has been formed to supply hIPSC-derived cells to the drug discovery and regenerative medicine sectors. The company is based on the research of Dr Ludovic Vallier, Dr Tamir Rashid and Professor Roger Pedersen of the Anne McLaren Laboratory of Regenerative Medicine.

Dr Vallier led a team, including Dr Rashid, Dr Nick Hannan and Candy Cho, that developed the technology to generate human liver cells (hepatocytes) in a highly reproducible and scalable manner for commercial use. This represents a major breakthrough in the costly and time-consuming process of developing new therapies. The technology has also been used to effectively model a diverse range of inherited liver diseases and has the potential to accelerate the development of new therapies for these conditions.

The liver is the key organ for metabolising drugs and removing toxins from the body. Consequently, it is often affected by toxic compounds. Demonstrating that a new drug candidate is free from liver toxicity is a key test in the development process, and it is a test that most drug candidates fail.

"If a drug's failure occurs in the clinical phase of development, a great deal of time and money will have been lost," said Dr Vallier. "Therefore, identifying toxic drugs as early as possible is vital to the safety and efficiency of the drug discovery process."

Currently, either primary human hepatocytes or immortalised cell lines are used for toxicity testing. Primary hepatocytes have a high degree of batch-to-batch variation, are expensive and difficult to obtain in suitable quantities, while immortalised cell lines are an inferior model for toxicity testing.

The hIPSC-derived cells produced by DefiniGEN, however, show many of the functional characteristics of primary cells, are highly reproducible and can be made in large quantities, making them ideal for toxicity testing.

In addition, the company's OptiDIFF platform has produced libraries of disease-modelled cells for a range of diseases, including the most common inherited metabolic conditions such as Familial hypercholesterolemia and Alpha 1 anti-trypsin disorder. The cells effectively demonstrate key pathologies of diseases and can be used to improve lead optimisation studies, assisting the development of new therapies for these conditions. The company will also develop pancreatic beta cell products which, in combination with hepatocyte products, will enable the optimised development of new therapeutics for diabetes.

"This is a technology whose time has come," said Marcus Yeo, DefiniGEN's CEO. "Cambridge has more expertise in the area of stem cells than perhaps anywhere else on earth, and now we are starting to see promising commercial opportunities which build on that expertise."


'/>"/>

Contact: Sarah Collins
sarah.collins@enterprise.cam.ac.uk
44-012-237-60335
Cambridge Enteprise University of Cambridge
Source:Eurekalert

Related biology news :

1. Tortoise and the hare: New drug stops rushing cancer cells, slow and steady healthy cells unharmed
2. Stem cells can repair a damaged cornea
3. Scientists produce eye structures from human blood-derived stem cells
4. Study demonstrates cells can acquire new functions through transcriptional regulatory network
5. Epigenetic signatures direct the repair potential of reprogrammed cells
6. Researchers print live cells with a standard inkjet printer
7. Nanopills release drugs directly from the inside of cells
8. Protein jailbreak helps breast cancer cells live
9. Newly found protein helps cells build tissues
10. BU researchers derive purified lung and thyroid progenitors from embryonic stem cells
11. Housekeeping mechanism for brain stem cells discovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/27/2016)... WEST CHESTER, Ohio , Jan. 27, 2016 /PRNewswire/ ... services supplier based in West Chester, Ohio ... and their award winning service staff, based in ... Track,s technical capacity and ability to provide modifications, installations ... John Dovalina , CEO of PLUS, commented, "PLUS ...
(Date:1/21/2016)... , January 21, 2016 ... a new market research report "Emotion Detection and Recognition ... Software Tools (Facial Expression, Voice Recognition and Others), ... Global forecast to 2020", published by MarketsandMarkets, the ... to reach USD 22.65 Billion by 2020, at ...
(Date:1/15/2016)... , Jan. 15, 2016 Recent publicized ... small to find new ways to ensure data security ... iOS and Android that ties ... biometrics, transforming it into a hardware authorization token. Customer ... swipe their fingerprint on their KodeKey enabled device to ...
Breaking Biology News(10 mins):
(Date:2/9/2016)... DelveInsight,s, "Protein-Tyrosine Phosphatase ... in depth insights on the pipeline drugs ... Phosphatase 1B (PTP1B) Inhibitors. The DelveInsight,s Report ... of development including Discovery, Pre-clinical, IND, Phase ... Report covers the product clinical trials information ...
(Date:2/8/2016)... 8, 2016  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced that it has entered ... Hercules Technology Growth Capital, Inc. and Hercules Technology ... financing. --> --> ... of financing under the loan and security agreement.  ...
(Date:2/8/2016)... ... February 08, 2016 , ... Thomas J. Todorow ... Executive Vice President for Corporate Services and the Chief Financial Officer at The ... Billing Operations, Treasury, Managed Care Contracting, Supply Chain, and Investments. , Prior to ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... wide range of loose, bulk foods at various stages of the production process. ... used to inspect large bulk products post packaging such as sacks of dry ...
Breaking Biology Technology: